Tasly Plans Non-Public Offering To Raise RMB 1 Billion, Aims For U.S. Market
This article was originally published in PharmAsia News
Executive Summary
Tasly Pharmaceutical recently announced plans to offer 20-40 million shares at no less than RMB 26.73 per share in a non-public offering to raise over RMB 1 billion in capital for seven construction and technological transformation projects